Servier Canada has announced Health Canada’s approval of VORANIGO (vorasidenib tablets) for Grade 2 isocitrate dehydrogenase (IDH)-mutant glioma treatment in adults and paediatric patients aged 12 years and above, following surgery. The approval represents the first therapy and a major advancement in treating the disease in almost 25 years. The gold standard of business intelligence.
VORANIGO, a dual inhibitor of mutant IDH1 and IDH2 enzymes, is designed to penetrate the blood-brain barrier. The treatment reduces the activity of these enzymes, helping to control the disease. The once-daily oral dosage offers patients the chance to manage their condition actively.
Following its , Canada has become the second country to authorise VORANIGO. Gliomas, the second-most common cancer type in Canadians under 40 years of age, spread within the brain and are not curable with current therapies. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form VORANIGO addresses the IDH mutation found in 60% to 70% of glioma patients. Servier Canada general manager Lucie Rousseau stated: “Patients living with Grade 2 IDH-mutant gliomas must contend with a grim pro.
